Added to YB: 2025-08-13
Pitch date: 2025-08-10
NVO [neutral]
Novo Nordisk A/S
-1.84%
current return
Author Info
Octopus Value is a private investor focusing on quality companies with margin of safety Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.4T
Pitch Price
DKK 327.17
Price Target
N/A
Dividend
3.64%
EV/EBITDA
8.92
P/E
13.70
EV/Sales
4.72
Sector
Pharmaceuticals
Category
turnaround
Novo Nordisk - H1 2025 Earnings Review
NVO (earnings overview): Despite -36% drop on FY25 guidance cut (8-14% CER sales growth, 10-16% EBIT growth), H1 shows solid 16% revenue growth, 25% EBIT growth. Wegovy adoption strong (+36% US, +298% intl), now in 35 markets. Threats: compounding competition, Rybelsus deprioritized. Likely near CapEx peak, FCF boom coming. Management appears conservative.
Read full article (9 min)